Skip to main content Back to Top
Advertisement

12/6/2019

Venlafaxine Hydrochloride Extended-Release Capsules

Products Affected - Description

    • Venlafaxine hydrochloride oral extended release capsule, Teva, 150 mg, bottle, 30 count, NDC 00093-7386-56
    • Venlafaxine hydrochloride oral extended release capsule, Teva, 150 mg, bottle, 500 count, NDC 00093-7386-05
    • Venlafaxine hydrochloride oral extended release capsule, Teva, 37.5 mg, bottle, 30 count, NDC 00093-7384-56
    • Venlafaxine hydrochloride oral extended release capsule, Teva, 37.5 mg, bottle, 90 count, NDC 00093-7384-98
    • Venlafaxine hydrochloride oral extended release capsule, Teva, 75 mg, bottle, 30 count, NDC 00093-7385-56
    • Venlafaxine hydrochloride oral extended release capsule, Teva, 75 mg, bottle, 90 count, NDC 00093-7385-98
    • Venlafaxine hydrochloride oral extended release capsule, Teva, 75 mg, bottle, 500 count, NDC 00093-7385-05
    • Venlafaxine hydrochloride oral extended release capsule, Zydus, 150 mg, bottle, 30 count, NDC 68382-0036-06 - discontinued
    • Venlafaxine hydrochloride oral extended release capsule, Zydus, 150 mg, bottle, 90 count, NDC 68382-0036-16
    • Venlafaxine hydrochloride oral extended release capsule, Zydus, 150 mg, bottle, 1000 count, NDC 68382-0036-10
    • Venlafaxine hydrochloride oral extended release capsule, Zydus, 37.5 mg, bottle, 30 count, NDC 68382-0034-06 - discontinued
    • Venlafaxine hydrochloride oral extended release capsule, Zydus, 37.5 mg, bottle, 90 count, NDC 68382-0034-16
    • Venlafaxine hydrochloride oral extended release capsule, Zydus, 37.5 mg, bottle, 1000 count, NDC 68382-0034-10
    • Venlafaxine hydrochloride oral extended release capsule, Zydus, 75 mg, bottle, 30 count, NDC 68382-0035-06 - discontinued
    • Venlafaxine hydrochloride oral extended release capsule, Zydus, 75 mg, bottle, 90 count, NDC 68382-0035-16
    • Venlafaxine hydrochloride oral extended release capsule, Zydus, 75 mg, bottle, 1000 count, NDC 68382-0035-10

Reason for the Shortage

    • Teva and Zydus did not provide a reason for the shortage.
    • Pfizer has Effexor XR capsules available.
    • Zydus has discontinued the 30 count presentations.

Available Products

    • Effexor XR oral extended release capsule, Pfizer, 150 mg, bottle, 15 count, NDC 00008-0836-20
    • Effexor XR oral extended release capsule, Pfizer, 150 mg, bottle, 30 count, NDC 00008-0836-21
    • Effexor XR oral extended release capsule, Pfizer, 150 mg, bottle, 90 count, NDC 00008-0836-22
    • Effexor XR oral extended release capsule, Pfizer, 150 mg, unit-dose blister pack, 100 count, NDC 00008-0836-03
    • Effexor XR oral extended release capsule, Pfizer, 37.5 mg, bottle, 15 count, NDC 00008-0837-20
    • Effexor XR oral extended release capsule, Pfizer, 37.5 mg, bottle, 30 count, NDC 00008-0837-21
    • Effexor XR oral extended release capsule, Pfizer, 37.5 mg, bottle, 90 count, NDC 00008-0837-22
    • Effexor XR oral extended release capsule, Pfizer, 37.5 mg, unit-dose blister pack, 100 count, NDC 00008-0837-03
    • Effexor XR oral extended release capsule, Pfizer, 75 mg, bottle, 15 count, NDC 00008-0833-20
    • Effexor XR oral extended release capsule, Pfizer, 75 mg, bottle, 30 count, NDC 00008-0833-21
    • Effexor XR oral extended release capsule, Pfizer, 75 mg, bottle, 90 count, NDC 00008-0833-22
    • Effexor XR oral extended release capsule, Pfizer, 75 mg, unit-dose blister pack, 100 count, NDC 00008-0833-03
    • Venlafaxine hydrochloride oral extended release capsule, Teva, 150 mg, bottle, 90 count, NDC 00093-7386-98
    • Venlafaxine hydrochloride oral extended release capsule, Teva, 37.5 mg, bottle, 500 count, NDC 00093-7384-05

Estimated Resupply Dates

    • Teva has venlafaxine 37.5 mg capsules in 30-count bottles on back order and the company estimates a release date of mid-December 2019; short-dated product available with an expiry of April 2020. The 37.5 mg capsules in 90-count bottles are on back order and the company estimates a release date of mid-January 2020. The venlafaxine 75 mg extended-release capsules in 30- and 90-count bottles are on back order and the company estimates a release date of mid-December 2020. The venlafaxine 75 mg capsules in 500-count bottles are on back order and the company estimates a release date of early-January 2020; short-dated product is available with an expiry of April 2020. the venlafaxine 150 mg extended-release capsules in 500- and 30-count bottles are on back order and the company estimates a release date of late-January 2020; short-dated 500-count bottles are available with an expiry of May 2020.
    • Zydus has venlafaxine extended-release 150 mg capsules in 1,000- and 90-count bottles and 75 mg capsules in 1,000- and 90-count bottles on allocation. The 37.5 mg capsules in 1,000- and 90-count bottles are on back order and the company cannot estimate a release date.

Updated

Updated December 6, 2019 by Anthony Trovato, PharmD, BCPS. Created August 30, 2019 by Leslie Jensen, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins